Endocrinology

Oral HRS-7535 added to metformin lowers HbA1c and causes modest weight loss

In a 16-week phase 2 randomized trial (n=194) oral HRS-7535 added to metformin reduced HbA1c by -1.82% (60 mg group) with placebo-adjusted differences up to -1.57% (all P<.001). Between 48.7% and 63.2% of treated patients achieved HbA1c <7.0% versus 15.4% with placebo. Weight fell modestly, greatest at 90 mg (-2.63%), and adverse events were mostly mild-to-moderate gastrointestinal events with rare hypoglycemia. These results are from a short (16-week) phase 2 program in China and require phase 3 confirmation and broader safety data before practice change. 1

UK survey: high GLP-1RA satisfaction but concerns and misuse reported

A cross-sectional UK survey (n=684; 544 current/former users) found high user satisfaction with GLP-1RAs for weight management. Respondents reported reduced energy, altered dietary habits, and concerns about loss of muscle mass and long-term safety. Many sourced medication from online pharmacies and social media, and a minority reported dose-exceeding behaviors consistent with misuse. These findings signal need for clinician counseling on sourcing, dose adherence, and monitoring muscle mass and functional status. 2

AI pre-ranking with cutoff improves efficiency and recall for living guideline maintenance

In a simulation using 854 articles across 38 topics, overarching single-database AI-enabled pre-ranking achieved 92–96% recall versus 76–89% for topic-specific searches. Overarching searches reduced screening workload by 63–70%, lowering articles screened per relevant study to 28–48 versus 76–160. Topic-specific searches were more efficient per topic but had significantly lower recall, and AI ranking added modest guideline-level gains. Consider overarching single-database AI pre-ranking to preserve recall while substantially reducing screening burden for living guidelines. 3